Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yoshida, Chisato ^a,b   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Sugyo, Aya ^a   Kikuchi, Tatsuya ^a   Koizumi, Mitsuru ^a   Arano, Yasushi ^b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; INDIUM 111; INDIUM MONOCLONAL ANTIBODY 12A8 I 111; INDIUM MONOCLONAL ANTIBODY 67A2 I 111; IODINE 125; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM MONOCLONAL ANTIBODY 12A8 Y 90; YTTRIUM MONOCLONAL ANTIBODY 67A2 Y 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CANCER RADIOTHERAPY; CELL INTERACTION; CELL SPECIFICITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-KIT; RADIOIMMUNOTHERAPY; SMALL CELL LUNG CARCINOMA; YTTRIUM RADIOISOTOPES;

EID: 84875044595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059248     Document Type: Article

References (39)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Seifter EJ, Ihde DC, (1988) Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 15: 278-299.
3. Elias AD, (1997) Small cell lung cancer: state-of-the-art therapy in 1996. Chest 112: 251S-258S.
4. Blackhall FH, Shepherd FA, (2007) Small cell lung cancer and targeted therapies. Curr Opin Oncol 19: 103-108.
5. Ronnstrand L, (2004) Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61: 2535-2548.
6. Kitamura Y, Hirotab S, (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61: 2924-2931.
7. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, et al. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130: 323-334.
8. Fischer B, Marinov M, Arcaro A, (2007) Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33: 391-406.
9. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, et al. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932.
10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
11. Lloyd KP, Krystal GW, (2002) Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer. Clin Lung Cancer 3: 213-218.
12. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, et al. (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9: 5880-5887.
13. Altundag O, Altundag K, Boruban C, Silay YS, Turen S, (2005) Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer 104: 2033,-2034 author reply 2034.
14. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, et al. (2005) Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103: 2128-2131.
15. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K, (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39: 793-799.
16. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, et al. (2005) KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23: 49-57.
17. Sogawa C, Tsuji AB, Sudo H, Sugyo A, Yoshida C, et al. (2010) C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol 37: 179-187.
18. Yoshida C, Tsuji AB, Sudo H, Sugyo A, Sogawa C, et al. (2011) Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. Nucl Med Biol 38: 331-337.
19. Cheson BD, (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391-398.
20. Kassis AI, (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38: 358-366.
21. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr, (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89.
22. Eckerman EF, Endo A (2010) MIRD: Radionuclide Data and Decay Schemes. Reston: Society for Nuclear Medicine.
23. Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, et al. (2010) Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging 37: 874-883.
24. Sudo H, Tsuji AB, Sugyo A, Ogawa Y, Sagara M, et al. (2012) ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Sci 103: 203-209.
25. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, et al. (1991) Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 51: 990-994.
26. Saga T, Sakahara H, Yao Z, Nakamoto Y, Sato N, et al. (1997) Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody. Jpn J Cancer Res 88: 1171-1180.
27. Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, et al. (1997) Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72: 901-912.
28. Lebitasy MP, Hedelin G, Purohit A, Moreau L, Klinzig F, et al. (2001) Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer 85: 808-815.
29. El Maalouf G, Rodier JM, Faivre S, Raymond E, (2007) Could we expect to improve survival in small cell lung cancer? Lung Cancer 57Suppl 2: S30-34.
30. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, et al. (1991) Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51: 2416-2419.
31. Krystal GW, Honsawek S, Litz J, Buchdunger E, (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326.
32. Wang WL, Healy ME, Sattler M, Verma S, Lin J, et al. (2000) Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19: 3521-3528.
33. Loke KS, Padhy AK, Ng DC, Goh AS, Divgi C, (2012) Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med 10: 122-138.
34. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, et al. (1991) Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296.
35. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, et al. (2012) c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. Oncogene 31: 869-883.
36. Packer AI, Besmer P, Bachvarova RF, (1995) Kit ligand mediates survival of type A spermatogonia and dividing spermatocytes in postnatal mouse testes. Mol Reprod Dev 42: 303-310.
37. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, et al. (2011) Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol 8: 720-734.
38. Sharkey RM, Goldenberg DM, (2011) Cancer radioimmunotherapy. Immunotherapy 3: 349-370.
39. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al. (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664-672.